Simple blood tests with AI help can predict who will get long COVID: Study
The study was done by a platoon from University College London in the UK.
via the web learning portal of the host university.
વયમર્યાદા માટેનો 29-09-2022 નો GR વાંચો અહીંથી
According to a recent study, a blood test taken at the time of COVID- 19 infection could prognosticate who's most likely to develop long COVID.
The study and its findings
Published in Lancet e Bio Medicine, the study was done by a platoon from University College London in the UK.
For the study, the experimenters anatomized proteins in the blood of healthcare workers infected with SARS- Co V- 2, comparing them to samples from healthcare workers who hadn't been infected.
generally, protein situations in the body are stable. still, the platoon set up a huge difference in situations of some of the proteins up to six weeks following infection, suggesting dislocation to several important natural processes.
They used an artificial intelligence( AI) algorithm and linked a “ hand ” in the cornucopia of different proteins that successfully prognosticated whether or not the person would go on to report patient symptoms a time after infection.
still, independent group of cases, a test could be offered alongside a polymer chain response( PCR) test that could prognosticate people’s liability of developing long COVID, If these findings are repeated in a larger.
still, the tool prognosticating long COVID still needs to be validated in an independent, larger group of cases.
DR. Gaby Capture's statement
Lead author Dr. Gaby Capture said “ The study shows that indeed mild or asymptomatic COVID- 19 disrupts the profile of proteins in our blood tube. This means that indeed mild COVID- 19 affects normal natural processes in a dramatic way, up to at least six weeks after infection. ”
“ still, using our approach, a test that predicts long COVID at the time of original infection could be rolled out snappily and in a cost-effective way, ” Capture added.
Dr. Wendy Heywood’s statement
Wendy Heywood said “ If we can identify people who are likely to develop long COVID, this opens the door to trialing treatments similar as antivirals at this earlier, original infection stage, to see if it can reduce the threat of latterly long COVID. ”
